Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$64.22M$64.22M+0.6% vs Q3 2015 Net Income$3.89M$3.89MN/M vs Q3 2015 EPS Diluted$0.08$0.08N/M vs Q3 2015 Gross Profit$27,612,000+57.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,298,000−63.5% Free Cash Flowderived-$5,403,000N/M Margins · derivedGross margin43.0%+15.5 pt vs Q3 2015
Operating margin9.0%+14.9 pt vs Q3 2015
Net margin6.1%+10.8 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end